Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans

Jeffrey Seow; Carl Graham; Blair Merrick; Sam Acors; Suzanne Pickering; Kathryn J. A. Steel; Oliver Hemmings; Aoife M. O’Byrne; Neophytos Kouphou; Rui Pedro Galão; Gilberto Betancor; Harry Wilson; Adrian W. Signell; Helena Winstone; Claire Kerridge; Isabella Huettner; Jose M. Jiménez-Guardeño; María José Lista; Nigel Temperton; Luke B. Snell; Karen Bisnauthsing; Amelia Moore; Adrian J. Green; Lauren Martinez; Brielle Stokes; Johanna Honey; Alba Izquierdo-Barras; Gill Arbane; Amita Patel; Mark Tan Kia Ik; Lorcan O’Connell; Geraldine O’Hara; Eithne MacMahon; Sam Douthwaite; Gaia Nebbia; Rahul Batra; Rocío T. Martínez-Nuñez; Manu Shankar‐Hari; Jonathan D. Edgeworth; Stuart J. D. Neil; Michael H. Malim; Katie J. Doores

doi:10.1038/s41564-020-00813-8

Keywords

SeroconversionAntibodyNeutralizing antibodyImmunologyAntibody responseSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)VirologyPopulationCoronavirus disease 2019 (COVID-19)MedicineBiologyDiseaseInternal medicineInfectious disease (medical specialty)

Affiliated Institutions

Related Publications

Robust neutralizing antibodies to SARS-CoV-2 infection persist for months

Ania Wajnberg , Fatima Amanat , Adolfo Firpo +15 more

SARS-CoV-2 antibodies persist As the number of daily COVID-19 cases continues to mount worldwide, the nature of the humoral immune response to severe acute respiratory syndrome ...

2020 Science 1241 citations

DNA vaccine protection against SARS-CoV-2 in rhesus macaques

Jingyou Yu , Lisa H. Tostanoski , Lauren Peter +51 more

Prototype DNA vaccines for SARS-CoV-2 The development of a vaccine to protect against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an urgent biomedical need. ...

2020 Science 1118 citations

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19

Peter Chen , Ajay Nirula , Barry N. Heller +19 more

In this interim analysis of a phase 2 trial, one of three doses of neutralizing antibody LY-CoV555 appeared to accelerate the natural decline in viral load over time, whereas th...

2020 New England Journal of Medicine 1412 citations

Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019

Juanjuan Zhao , Quan Yuan , Haiyan Wang +22 more

Abstract Background The novel coronavirus SARS-CoV-2 is a newly emerging virus. The antibody response in infected patients remains largely unknown, and the clinical value of ant...

2020 Clinical Infectious Diseases 2652 citations

Severe Acute Respiratory Syndrome Coronavirus 2−Specific Antibody Responses in Coronavirus Disease Patients

Nisreen M.A. Okba , Marcel A. Müller , Wentao Li +16 more

A new coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has recently emerged to cause a human pandemic. Although molecular diagnostic tests were rapidly...

2020 Emerging infectious diseases 1653 citations

Publication Info

Year: 2020
Type: article
Volume: 5
Issue: 12
Pages: 1598-1607
Citations: 1360
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1360

OpenAlex

Cite This

APA Style

                            
                                
                                    Jeffrey Seow, 
                                
                                    Carl Graham, 
                                
                                    Blair Merrick
                                
                                et al.
                            
                            (2020). 
                            Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. 
                            Nature Microbiology
                            , 5
                            (12)
                            , 1598-1607.
                            https://doi.org/10.1038/s41564-020-00813-8
                        

Identifiers

DOI: 10.1038/s41564-020-00813-8